Fig. 2

Leronlimab blocks human CCL5-CCR5-mediated signaling in human breast cancer cells. a MDA-MB-231-CCR5 cells were assessed for Ca^+ 2 fluxes using Fluo-4 as a calcium concentration indicator. Fluorescence was measured at time points after the addition of the CCR5 ligand, CCL5, in the presence of either CCR5 inhibitors (leronlimab, vicriviroc) or control IgG. b–e Quantitation of the time course of Ca^+ 2-induced fluorescence was obtained from living cell imaging (a–d). The CCR5 antagonist, vicriviroc, was used as a positive control (a, e). Leronlimab reduced CCL5-induced calcium responses in MDA-MB-231-CCR5 cells (1.23 ± 0.10, N = 10 for control cells and 0.54 ± 0.13 N = 12 for leronlimab-treated cells. P < 0.001 at calcium peak induce by CCL5)